METHOD FOR DETERMINING THE RISK OF DEVELOPING CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH STAGE II ESSENTIAL ARTERIAL HYPERTENSION WITHIN 12 MONTHS AFTER COVID-19 Russian patent published in 2022 - IPC G01N33/68 G01N33/573 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to immunology and cardiology, and can be used to determine the risk of developing cardiovascular complications in patients with stage II essential arterial hypertension within 12 months after COVID-19. The levels of high mobility group box 1 protein (HMGB1) in the blood are taken into account 10 and 30 days after laboratory recovery - two negative PCR results for SARS-CoV-2 RNA. A coefficient reflecting the ratio of HMGB1 at day 30 to HMGB1 at day 10 is calculated. A high risk is predicted when the level of HMGB1 in the blood serum of patients with essential arterial hypertension on day 10 after COVID-19 is 5400 pg/ml or more and the ratio of HMGB1 levels on day 30 to HMGB1 on day 10 is 2 or more. Average risk is predicted at the level of HMGB1 in the blood serum of patients with essential arterial hypertension on the 10th day after COVID-19 of 5400 pg/ml or more and the ratio of HMGB1 on day 30 to HMGB1 on day 10 is from 1.5 to 2. Low risk is predicted at the level of HMGB1 in the blood serum of patients with essential arterial hypertension on day 10 after COVID-19, less than 5400 pg/ml.

EFFECT: method provides the possibility of increasing the accuracy of calculating the personalized risk of developing fatal and non-fatal cardiovascular complications (myocardial infarction, acute cerebrovascular accident) in patients with stage II essential arterial hypertension within 1 year after undergoing COVID-19 due to the dynamic study of HMGB1 in the blood (10 and 30 days) after laboratory recovery.

1 cl, 1 tbl, 3 ex